


Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	09/754,775
		Filing Date	January 4, 2001
		First Named Inventor	Grainger, David
		Group Art Unit	1617
		Examiner Name	Kim, Jennifer
Sheet 1 of 4		Attorney Docket No: 295.009US3	

US PATENT DOCUMENTS				
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-4,826,876	05/02/1989	Ellis, D., et al.	12/21/1987
	US-7,094,550	08/22/2006	Grainger, David J., et al.	03/26/2002

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
	EP-0290012A1	11/09/1988	Marquardt, H., et al.	
	JP-04-501848 (w/ English Abstract)	04/02/1992	Hanson, S., et al.	
	WO-89/05148A1	06/15/1989	Harker, L. A., et al.	
	WO-92/00330A1	01/09/1992	Iwata, K. K., et al.	
	WO-92/08480A1	05/29/1992	Owaga, Y., et al.	
	WO-94/05265A1	03/17/1994	Berde, C. B., et al.	
	WO-94/26303A1	11/24/1994	Grainger, D. J., et al.	
	WO-96/40098A2	12/19/1996	Grainger, D. J., et al.	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
,		"1992 Keystone Symposia on Molecular and Cellular Biology. Inflammation, growth regulatory molecules and atherosclerosis. January 13-19, 1992. Abstracts", J Cell Biochem Suppl., 50(S16A), Abstracts E111,(1992), 1-30	
		"Application Serial No. 08/973,570 (Atty. Ref. 295.009US2), Non Final Office Action mailed 02-01-1999", 6 pgs	
		"Application Serial No. 08/973,570 (Atty. Ref. 295.009US2), Non Final Office Action mailed 09-29-1999", 5 pgs	
		"Application Serial No. 08/973,570 (Atty. Ref. 295.009US2), Notice of Allowance mailed 09-25-2000", 2 pgs	
		"Application Serial No. 08/973,570 (Atty. Ref. 295.009US2), Preliminary Amendment filed 12-05-1997", 2 pgs	
		"Application Serial No. 08/973,570 (Atty. Ref. 295.009US2), Response filed 03-21-2000 to Non Final Office Action mailed 09-29-1999", 4 pgs.	
		"Application Serial No. 08/973,570 (Atty. Ref. 295.009US2), Response filed 07-30-1999 to Non Final Office Action mailed 02-01-1999", 4 pgs	
		"Application Serial No. 08/973,570 (Atty. Ref. 295.009US2), Response filed 09-08-2000 to Final Office Action mailed 06-08-2000", 3 pgs	
		"Application Serial No. 08/973,570 (Atty. Ref. 295.009US2), Final Office Action mailed 06-08-2000", 4 pgs.	

EXAMINER

DATE CONSIDERED

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	09/754,775
		Filing Date	January 4, 2001
		First Named Inventor	Grainger, David
		Group Art Unit	1617
		Examiner Name	Kim, Jennifer
Sheet 2 of 4		Attorney Docket No: 295.009US3	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		"Application Serial No. 10/729,056 (Atty Ref. No. 295.009US4), Amendment and Response filed 10-01-2007 to Non-Final Office Action dated 07-03-2007", 11 pgs.	
		"Application Serial No. 10/729,056 (Atty Ref 295.009US4), Non-Final Office Action mailed 09-03-2008", 16 pgs.	
		"Application Serial No. 10/729,056 (Atty. Ref. 295.009US4), Final Office Action mailed 12-11-2007", 20 pgs.	
		"Application Serial No. 10/729,056 (Atty. Ref. 295.009US4), Non Final Office Action mailed 07-03-2007", 17 pgs.	
		"Application Serial No. 10/729,056 (Atty. Ref. No. 295.009US4), Amendment and Response filed 3-11-2008 to Final Office Action mailed 12-11-2007", 11 pgs.	
		"Application Serial No. 11/231,256 (Atty Ref 295.011US3), Notice of Allowance mailed 07-29-2008", 4 pgs.	
		"Application Serial No. 11/231,256 (Atty Ref 295.011US3), Response filed 5-29-2008 to Final Office Action mailed 2-29-2008", 4 pgs.	
		"Application Serial No. 11/231,256 (Atty Ref. 295.011US2), Amendment and Response filed 12-06-2007 to Office Action mailed 09-26-2007", 5 pgs	
		"Application Serial No. 11/231,256 (Atty. Ref. 295.011US3), Final Office Action mailed 02-29-2008.", 8 pgs.	
		"Application Serial No. 11/231256 (Atty. Ref. 295.011US3), Non Final Office Action Mailed 09-26-2007", 7 pgs	
		"Application Serial No. 96921577.1 (Atty Ref 295.009EP1), Communication mailed 4-6-2006", 3 pgs.	
		"Application Serial No. 96921577.1 (Atty Ref 295.009EP1), Communication mailed 6-16-2003", 13 pgs.	
		"Application Serial No. 96921577.1 (Atty Ref 295.009EP1), Response filed 12-12-2006", 21 pgs.	
		"European Application Serial No 07021554.6 (Atty Ref 295.009EP2), Extended European Search Report mailed 09-09-2008", 8 pgs.	
		"International Application Serial No. PCT/US96/10211 (Atty Ref 295.009WO1), International Search Report mailed 5-20-1997", 5 pgs.	
		"International Application Serial No. PCT/US96/10211 (Atty Ref 295.009WO1), Written Opinion mailed 6-20-1997", 8 pgs.	
		"Japanese Application No. 9-502239 (Atty Ref 295.009JP1), Notice of Reasons for Rejection mailed 10-30-2007", (w/ English Translation),19 pgs.	
		"Japanese Application No. 9-502239 (Atty Ref 295.009JP1), Response filed 4-30-2008 to Notice of Reason for Rejection mailed 10-30-2007", (w/ English Translation), 78 pgs.	
		BJÖRKERUD, S., et al., "Effects of Transforming Growth Factor-β1 on Human Aterial Smooth Muscle Cells In Vitro", <u>Arteriosclerosis and Thrombosis</u> ; 11, (2007),(1991), 892-902	

EXAMINER

DATE CONSIDERED

Substitute for form 1449A/PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		<i>Complete if Known</i>	
		Application Number	09/754,775
		Filing Date	January 4, 2001
		First Named Inventor	Grainger, David
		Group Art Unit	1617
		Examiner Name	Kim, Jennifer
Sheet 3 of 4		Attorney Docket No: 295.009US3	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DRESEL, P E., et al., "Cytochalasin-B and phloretin depress contraction and relaxation of aortic smooth muscle", <u>Eur J Pharmacol</u> , 144(2), (1987), 153-157	
		GRAINGER, D. J., "Control of the Proliferation and Differentiation of Vascular Smooth Muscle Cells", <u>PhD Thesis. University of Cambridge</u> , (September, 1992), 192 pgs.	
		GRAINGER, D. J., et al., "Tamoxifen: Teaching an Old Drug new Tricks?", <u>Nature Medicine</u> , 2(4), (April, 1996), 381-385	
		KANGAS, L., "Introduction to toremifene", <u>Breast Cancer Res Treat</u> , (1990-Aug-16), S 3-7	
		KHANNA, A. K., "Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus.", <u>Transplantation</u> , 70(4), (Aug. 27, 2000), 690-694	
		KHANNA, A., "TGF-BETA Provides the Rationale for the Synergistic Immunosuppression with rapamycin (RaPA), Cyclosporine (CsA) and Tacrolimus (TAC).", <u>Transplantation</u> , 67(7), (Abstract Only) (April 15, 1999), 2 pgs.	
		MCKENNEY, P. A., et al., "Cyclosporine A Does Not Inhibit Restenosis in Experimental Angioplasty", <u>Circulation</u> , 84(4), (1991), (Abstract 0278), 1 pg.	
		NUOVO, M. A., et al., "Endomaterial Polyps in Postmenopausal Patients receiving Tamoxifen", <u>Int J Of Gynecological Pathology</u> ; Raven Press Ltd., NY, (1989), 125-131	
		OWENS, G. K., et al., "Transforming Growth Factor β -induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells", <u>J. Cell. Biol.</u> , 107 (2), (August, 1988), 771-780	
		POTTER, G. A., et al., "A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism", <u>Carcinogenesis</u> , 15 (3), (1994), 439-442	
		SAWADA, T., et al., "Fifty two-week Oral Toxicity Study of Toremifene Citrate (NK622)", <u>Pharmacometrics</u> , (w/ English Translation), (May 11, 1992), 357-373 (33 pgs)	
		STOCKWELL, B. R., et al., "TGF- β -signaling with small molecule FKBP12 antagonists that bind myristoylated FKBP12-TGF- β type I receptor fusion proteins.", <u>Chem Biol.</u> 5(7), (July, 1998), 385-95	
		STRAUSS, B H., et al., "Angiographic Predictors of Restenosis in the Coronary Wallstent.", <u>Circulation</u> , 82(4), (Abstract No. 2142), (1990), 1 pg.	
		SWINFORD, R. D., et al., "Rapamycin (RAPA) enhances transforming growth factor beta (TGF-b1) Expression in Immortalized Rat Proximal Tubules Cells (IRPTC)", <u>American Society of Transplant Physicians (ASTP 1998 Abstracts)</u> , (Abstract No. 396), (1998), 1 pg.	
		WÄRRI, A. M., et al., "Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro", <u>J Natl Cancer Inst.</u> ; 85(17), (1993), 1412-1418	

EXAMINER

DATE CONSIDERED

Substitute for form 1449A/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	09/754,775
		Filing Date	January 4, 2001
		First Named Inventor	Grainger, David
		Group Art Unit	1617
		Examiner Name	Kim, Jennifer
Sheet 4 of 4		Attorney Docket No: 295.009US3	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		WASOWSKA, B. A., et al., "Adjunctive rapamycin and CsA treatment inhibits monocyte/macrophage associated cytokines/chemokines in sensitized cardiac graft recipients", <i>Transplantation</i> , 71(8), (2001), 1179-1183	
		YOUNG, H., et al., "Pharmacokinetics and Biodistribution of Radiolabelled Idoxifene: Prospects for the Use of PET in the Evaluation of a Novel Antioestrogen for Cancer Therapy", <i>Nucl. Med. Bio.</i> 2(4), (1995), 405-411	

EXAMINER

DATE CONSIDERED